SCHEMBL24967958

SCHEMBL24967958

O=C(OCCc1c[nH]c(=O)c(C(F)(F)F)c1)N1CCN(c2cnc(C(F)(F)F)cn2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
CHRM2 P08172 1/20 0.39
SLC6A9 P48067 1/20 0.39
MAPT P10636 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 2/20 0.38
PARP1 P09874 2/20 0.38
TIPARP Q7Z3E1 4/20 0.36
ITGB2 P05107 1/20 0.36
ICAM1 P05362 1/20 0.36
ITGAL P20701 1/20 0.36
KDM4E B2RXH2 2/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
HSD17B10 Q99714 1/20 0.35
LCAT P04180 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24968471 0.87 SMN1; SMN2 (0.60) HPGDSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL24968335 0.84 TIPARP (0.48) HPGDSMN1; SMN2PARP1TIPARP
SCHEMBL24968229 0.84 TIPARP (0.52) HPGDSMN1; SMN2MEN1KMT2APARP1
SCHEMBL24967941 0.83 TIPARP (0.43) HPGDSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL24967955 0.82 TIPARP (0.42) HPGDSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL24968351 0.81 MEN1 (0.54) HPGDSMN1; SMN2SLC6A9MAPTMEN1
SCHEMBL24967960 0.81 MEN1 (0.49) HPGDSMN1; SMN2SLC6A9MAPTMEN1
SCHEMBL24967947 0.81 TIPARP (0.46) HPGDSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL24968854 0.80 TIPARP (0.42) HPGDSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL24968233 0.80 KMT2A (0.48) HPGDSMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240351997-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) 2024-10-24 US disclosed
EP-4378938-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2024-06-05 EP disclosed
WO-2023006013-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240351997-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF PARP6, PARP4, PARP3 HPGD 739/4885SMN1; SMN2 3311/4885CHRM2 4881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.